Berdazimer Sodium Patent Expiration
Berdazimer Sodium is used for treating viral infections, dermatological conditions, and malignant lesions, as well as improving skin ailments. It was first introduced by Lnhc Inc
Berdazimer Sodium Patents
Given below is the list of patents protecting Berdazimer Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zelsuvmi | US10322081 | Topical antiviral compositions and methods of using the same | Jul 10, 2035 | Lnhc |
| Zelsuvmi | US10736839 | Topical antiviral compositions, delivery systems, and methods of using the same | Jul 10, 2035 | Lnhc |
| Zelsuvmi | US11040006 | Topical antiviral compositions, delivery systems, and methods of using the same | Jul 10, 2035 | Lnhc |
| Zelsuvmi | US11723858 | Topical antiviral compositions, delivery systems, and methods of using the same | Jul 10, 2035 | Lnhc |
| Zelsuvmi | US10258564 | Topical compositions and methods of using the same | Nov 22, 2034 | Lnhc |
| Zelsuvmi | US11285098 | Topical compositions and methods of using the same | Feb 28, 2034 | Lnhc |
| Zelsuvmi | US9855211 | Topical compositions and methods of using the same | Feb 27, 2034 | Lnhc |
| Zelsuvmi | US10265334 | Anhydrous compositions | Jul 03, 2032 | Lnhc |
| Zelsuvmi | US9289442 | Topical compositions | Jul 03, 2032 | Lnhc |
| Zelsuvmi | US9526738 | Topical gels and methods of using the same | Sep 03, 2031 | Lnhc |
| Zelsuvmi | US10376538 | Topical gels and methods of using the same | Aug 20, 2030 | Lnhc |
| Zelsuvmi | US9737561 | Topical gels and methods of using the same | Aug 20, 2030 | Lnhc |
| Zelsuvmi | US8282967 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | May 30, 2026 | Lnhc |
| Zelsuvmi | US8956658 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | May 30, 2026 | Lnhc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Berdazimer Sodium's patents.
Latest Legal Activities on Berdazimer Sodium's Patents
Given below is the list recent legal activities going on the following patents of Berdazimer Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 27 Jun, 2024 | US9526738 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 22 Mar, 2024 | US8282967 |
| Change in Power of Attorney (May Include Associate POA) Critical | 05 Mar, 2024 | US9855211 |
| Email Notification Critical | 05 Mar, 2024 | US9855211 |
| Initial letter Re: PTE Application to regulating agency | 04 Mar, 2024 | US9855211 |
| Patent Term Extension Application under 35 USC 156 Filed | 01 Mar, 2024 | US9855211 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Feb, 2024 | US10736839 |
| Patent Issue Date Used in PTA Calculation Critical | 15 Aug, 2023 | US11723858 |
| Email Notification Critical | 15 Aug, 2023 | US11723858 |
| Mail Patent eGrant Notification | 15 Aug, 2023 | US11723858 |
Berdazimer Sodium's Family Patents
